Axsome Therapeutics Inc. (AXSM) and Selecta Biosciences Inc. (NASDAQ:SELB) Comparing side by side

We will be contrasting the differences between Axsome Therapeutics Inc. (NASDAQ:AXSM) and Selecta Biosciences Inc. (NASDAQ:SELB) as far as institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Axsome Therapeutics Inc. N/A 0.00 30.97M -1.13 0.00
Selecta Biosciences Inc. N/A 114.93 65.34M -3.14 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Axsome Therapeutics Inc. and Selecta Biosciences Inc.

Profitability

Table 2 represents Axsome Therapeutics Inc. (NASDAQ:AXSM) and Selecta Biosciences Inc. (NASDAQ:SELB)’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Axsome Therapeutics Inc. 0.00% -310.9% -113.7%
Selecta Biosciences Inc. 0.00% -220.1% -86.5%

Liquidity

Axsome Therapeutics Inc.’s Current Ratio is 1.5 while its Quick Ratio is 1.5. On the competitive side is, Selecta Biosciences Inc. which has a 1.6 Current Ratio and a 1.6 Quick Ratio. Selecta Biosciences Inc. is better positioned to pay off short and long-term obligations compared to Axsome Therapeutics Inc.

Analyst Ratings

The Ratings and Recommendations for Axsome Therapeutics Inc. and Selecta Biosciences Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Axsome Therapeutics Inc. 0 0 2 3.00
Selecta Biosciences Inc. 0 0 0 0.00

Axsome Therapeutics Inc. has a 64.91% upside potential and an average price target of $25.

Institutional & Insider Ownership

Axsome Therapeutics Inc. and Selecta Biosciences Inc. has shares owned by institutional investors as follows: 12.9% and 53.3%. About 30.4% of Axsome Therapeutics Inc.’s share are owned by insiders. On the other hand, insiders owned about 0.2% of Selecta Biosciences Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Axsome Therapeutics Inc. -12.24% -3.46% 154.72% 145.45% 217.65% 187.23%
Selecta Biosciences Inc. -8.64% 28.03% -66.39% -84.51% -78.5% -24.44%

For the past year Axsome Therapeutics Inc. had bullish trend while Selecta Biosciences Inc. had bearish trend.

Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the management of central nervous system (CNS) disorders. The companyÂ’s product candidates include AXS-05 that is in Phase III trial for the treatment of treatment resistant depression and AlzheimerÂ’s disease agitation; and AXS-02, which is in Phase III trial to treat complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes. It is also developing AXS-06, a preclinical product candidate for CNS disorders, including chronic pain. The company was founded in 2012 and is based in New York, New York.

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its lead product candidate is SEL-212, which is in phase I/II clinical trials for the treatment of refractory and chronic tophaceous gout. Selecta Biosciences, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts.